

PF-07321332

Cat. # F1000-2, F1000-10, F1000-50

Also Known as: PF07321332, Paxlovid, 3CL protease inhibitor

Formula: $C_{23}H_{32}F_3N_5O_4$

MW: 499.53 g/mol

CAS No.: 2628280-40-8

Source: Synthetic

Form: Powder


Solubility: Up to 50 mg/ml in DMSO

Preparation of Stocks: 10 mg/mL = 20 mM

Quality Assurance: > 99% purity assayed by HPLC. Structure validated by HNMR.

Description: PF-07321332 is an orally active covalent inhibitor of the 3C-like protease by direct binding of the catalytic cysteine 145. 3CL protease cleaves polyproteins 1a and 1ab of SARS-CoV-2, a step required for reproduce the virus. The PF-07321332/ritonavir combination drug (trade name Paxlovid) is efficient for the treatment of COVID-19 as, in November 2021, Pfizer announced phase 2/3 clinal trial results that the drug treatment reduced 89% in hospitalizations when given within three days after symptom onset. This product is for research use only.

Image:



HPLC analyses of PF-07321332

Storage: Eligible for room temperature shipping. Store at -20°C upon receiving. Avoid multiple freeze-thaw cycles after dissolving in DMSO.

Literature: Vandyck K, Deval J, Curr. Opin. in Virology. 2021, 49, 36-40.